Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents

Pharmacy World and Science

Volumn 19, Issue 1, 1997, Pages 13-34

  Booij, Leo H D J ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

aminosteroids; benzylisoquinolines; cardiovascular effects; depolarizing relaxants; drug interactions; effect of hepatic diseases; effect of renal diseases; histamine release; muscle relaxants; neuromuscular diseases; non depolarizing relaxants

Indexed keywords

ALCURONIUM; AMINOPHYLLINE; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ATRACURIUM; CALCIUM ANTAGONIST; CISATRACURIUM; CYCLOSPORIN; DILTIAZEM; DIMETHYLTUBOCURARINE CHLORIDE; DOXACURIUM; GALLAMINE; MAGNESIUM SULFATE; MIVACURIUM; MUSCLE RELAXANT AGENT; NEUROMUSCULAR BLOCKING AGENT; NIFEDIPINE; PANCURONIUM; PHENYTOIN; PIPECURONIUM; QUININE; ROCURONIUM; SUXAMETHONIUM; THEOPHYLLINE; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; VECURONIUM;

BRADYCARDIA; CARDIOVASCULAR EFFECT; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG METABOLISM; HISTAMINE RELEASE; HUMAN; HYPOTENSION; MYALGIA; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR TRANSMISSION; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; STEREOISOMERISM;

BODY TEMPERATURE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DRUG INTERACTIONS; HISTAMINE RELEASE; HUMANS; KIDNEY DISEASES; LIVER DISEASES; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR DEPOLARIZING AGENTS; NEUROMUSCULAR NONDEPOLARIZING AGENTS; SUCCINYLCHOLINE; WATER-ELECTROLYTE BALANCE;

EID: 0030956248     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008641427473     Document Type: Review

References (301)

1. Katz RL. Neuromuscular effects of d-tubocurarine, edrophonium and neostigmine in man. Anesthesiology 1967;28: 327-36.
2. Ritter DM, Rettke SR, Ilstrup DM, Burritt MF. Effect of plasma cholinesterase activity on the duration of action of succinylcholine in patients with genotypically normal enzyme. Anesth Analg 1988;67:1123-6.
3. VanLinthout LEH, van Egmond J, De Boo T, Lerou JGC, Wevers RA, Booij LHDJ. Factors affecting magnitude and time course of neuromuscular block produced by suxamethonium. Br J Anaesth 1992;69:29-35.
4. Schulte-Sasse U, Eberlein HJ, Kirch EM, Schlittenhardt W, Schmücker, Underwood D. Has the routine use of Succinylcholine come to an end after forty years? Anaesth Intensivemed 1993;34:230-4.
5. Zahl K, Apfelbaum JL. Muscle pain occurs after outpatient laparoscopy despite the substitution of vecuronium for succinylcholine. Anesthesiology 1989;70:408-11.
6. Trépanier CA, Brousseau C, Lacerte L. Myalgia in outpatient surgery: comparison of atracurium and succinylcholine. Can J Anaesth 1988;35:255-9.
7. Erkola O. Effects of precurarisation on suxamethonium-induced postoperative myalgia during the first trimester of pregnancy. Acta Anaesthesiol.Scand. 1990;34:63-76.
8. Pace NL. Prevention of succinylcholine myalgias: A metaanalysis. Anesth Analg 1990;70:477-83.
9. McLouglin C, Elliott P, McCarthy G, Mirakhur RK. Muscle pains and biochemical changes following suxamethonium administration after six pretreatment regimes. Anaesthesia 1992;47:202-6.
10. Warner LO, Brener DL, Davidson PJ, Rogers GL, Beach TP. Effects of lidocaine, succinylcholine, and tracheal intubation on intraocular pressure in children anaesthetized with halothane-nitrous oxide. Anesth Analg 1989;69:687-90.
11. Libonati MM, Leahy JJ, Ellison N. The use of succinylcholine in open eye surgery. Anesthesiology 1985;62:637-40.
12. Kelly RE, Dinner M, Turner LS, Haik B, Abramson DH, Daines P. Succinylcholine increased intraocular pressure in the human eye with the extraocular muscles detached. Anesthesiology 1993;79:948-52.
13. Smith G, Dalling R, Williams TIR. Gastro-oesophageal pressure gradient changes produces by induction of anaesthesia and suxamethonium. Br J Anaesth 1978;50:1137-43.
14. Minton MD, Grosslight K, Stirt JA, Bedford RF. Increases in intracranial pressure from succinylcholine: prevention by prior nondepolarising blockade. Anesthesiology 1986;65: 165-9.
15. Kovarik WD, Mayberg TS, Lam AL, Mathisen TL, Winn HR. Succinylcholine does not change intracranial pressure, cerebral blood flow velocity, or the electroencephalogram in patients with neurologic injury. Anesth Analg 1994;78:469-73.
16. Artru AA. Muscle relaxation with succinylcholine or vecuronium does not alter the rate of CSF production or resistance to reabsorption of CSF in dogs. Anesthesiology 1988;68: 392-6.
17. Thiagarajah S, Sophie S, Lear E, Azar I, Frost EAM. Effect of suxamethonium on the ICP of cats with and without thiopentone pretreatment. Br J Anaesth. 1988;60:157-60.
18. Smith CE, Donati F, Bevan DR. Effects of succinylcholine at the masseter and adductor pollicis muscle in adults. Anesth Analg 1989;69:159-62.
19. VanderSpek AFL, Reynolda PI, Fang WB, Ashton-Miller JA, Stohles CS, Schork MA. Changes in resistance to mouth opening induced by depolarizing and non-depolarizing neuromuscular relaxants. Br J Anaesth 1990;64:21-7.
20. O'Flynn RP, Shutack JG, Rosenberg H, Fletcher JE. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. Anesthesiology 1994;80:1228-33.
21. Manninen PH, Makendran B, Gelb AW, Merchant RN. Succinylcholine does not increase serum potassium levels in patients with acutely ruptured cerebral aneurysms. Anesth Analg 1990;70:172-5.
22. Koller ME, Breivik H, Grieder P, Jones DJ, Smith RB. Synergistic effect of acidosis and succinyl-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand 1984;28:87-90.
23. Schwartz DE, Kelly B, Caldwell JE, Carlisle AS, Cohen NH. Succinylcholine-induced hyperkalemic arrest in a patient with severe metabolic acidosis and exsanguinating hemorrhage. Anesth Analg 1992;75:291-3.
24. Brown TCK, Bell B. Electromyographic responses to small doses of suxamethonium in children after burns. Br J Anaesth 1987;59:1017-21.
25. Viby-Mogensen J, Hanel HK, Hansen E, Sorensen B, Graae J. Serum cholinesterase activity in burned patients. I. Biochemical findings. Acta Anaesthesiol Scand 1975;19: 159-79.
26. Gronert GA, Theye RA. Pathophysiology of hyperkalemia produced by succinylcholine. Anesthesiology 1975;43:89-99.
27. Martin J, Goldhill DR, Goudsouzian NG. Clinical pharmacology of muscle relaxants in patients with burns. J Clin Pharmacol 1986;26:680-5.
28. Rosenberg H, Gronert GA. Intractable cardiac arrest in children given succinylcholine. Anesthesiology 1992;77:1054.
29. Marell RC, Berman JM, Royster RI, Petrozza PH, Kelly JS, Colonna DM. Revised label regarding use of succinylcholine in children and adolescents: I. Anesthesiology 1994;80:242.
30. Badgwell JM, Hall SC, Lockhart C. Revised label regarding use of succinylcholine in children and adolescents: II. Anesthesiology 1994;80:243.
31. Lerman J, Berdock JE, Bissonnette B, Braude BM, Cox P, Crawford MW, Creighton RE, Dodgson BG, Fear DW, Gerus LR et al. Succinylcholine warning. Can J Anaesth 1993;41:165.
32. Katz L, Wright C, Harter J, Zung M, Scally D, Spyker D. In reply. Anesthesiology 1994;80:243-4.
33. Kent RS. In reply. Anesthesiology 1994;80:244-5.
34. Rosenberg H, Gronert GA. Intractable cardiac arrest in children given succinylcholine. Anesthesiology 1992;77:1054.
35. Sorensen M, Engbaek J, Viby-Mogensen J, Guldager H, Jensen FM. Bradycardia and cardiac asystole following a single injection of suxamethonium. Acta Anaesthesiol Scand 1984;28:232-5.
36. Nigrovic V, McCullough LS, Watskol A, Levin JA, Martin JT. Succinylcholine-induced increases in plasma catecholamine levels in humans. Anesth Analg 1983;62:627-32.
37. Oshita S, Denda S, Fujiwara Y, Takeshida H, Kosaka F. Pretreatment with d-tubocurarine, vecuronium, and pancuronium attenuates succinylcholine-induced increases in plasma norepinephrine concentrations in humans. Anesth Analg 1991;72:84-8.
38. Yasuda I, Hirano T, Amaha K, Fudeta H, Obara S. Chronotropic effects of succinylcholine and succinylmonocholine on sinoatrial node. Anesthesiology 1982;57:289-92.
39. Leiman BC, Katz J, Butler BD. Mechanisms of succinylcholine-induced arrhythmias in hypoxic or hypoxic-hypercarbic dogs. Anesth Anal 1987;66:1292-7.
40. Bowman WC. Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesth Analg 1980;59:935-43.
41. Greenawalt III, JW. Succinylcholine-induced hyperkalemia 8 weeks after a brief paraplegic episode. Anesth Analg 1992;75:294-5.
42. Orndahl G, Sternberg K. Myotonic human musculature: stimulation with depolarizing agents. Mechanical registration of the effect of succinylcholine, succinylmonocholine, and decamethonium. Acta Med.Scand. 1962;172:3 (suppl.389):3-29.
43. Baraka A, Baroody M, Yazbeck V. Repeated doses of suxamethonium in the myasthenic patient. Anaesthesia 1993;48:782-4.
44. Eisenkraft JB, Book WJ, Mann SM, Papatestas AE, Hubbard M. Resistance to succinylcholine in myasthenia gravis: a dose response study. Anesthesiology 1988;69:760-3.
45. Wainwright AP, Brodrick PM. Suxamethonium in myasthenia gravis. Anaesthesia 1987;42:950-7.
46. Vanlinthout LEH, Robertson EN, Booij LHDJ. Response to suxamethonium during propofol-fentanyl-N2O/O2 anaesthesia in a patient with active myasthenia gravis receiving chronic anticholinesterase therapy. Anaesthesia 1994;49:509-11.
47. Baraka A. Suxamethonium block in the myasthenic patient. Correlation with plasma cholinesterase. Anaesthesia 1992;47:217-19.
48. Whittaker M, Britten JJ. Phenotyping of individuals sensitive to suxamethonium. Br J Anaesth 1987;59:1052-5.
49. Robertson GS. Serum cholinesterase deficiency I. Disease and inheritance. Br J Anaesth 1966;38:355-60.
50. Robertson GS. Serum cholinesterase deficiency II pregnancy. Br J Anaesth 1966;38:361-4.
51. Robson N, Robertson I, Whittaker. Plasma cholinesterase changes in the puerperium. Anaesthesia 1986;41:243-9.
52. Matsuki A, Oyama T. Effects of extracorporeal circulation on plasma cholinesterase activity in man. Agressologie 1981;22:79-81.
53. Shearer ES, Russel GN. The effect of cardiopulmonary bypass on cholinesterase activity. Anaesthesia 1993;48:293-6.
54. Whittaker M. Plasma cholinesterase variants and the anaesthetist. Anaesthesia 1980;35:174-97.
55. Maddineni VR, Mirakhur RK, McCoy EP. Plasma cholinesterase activity in elderly and young patients. Br J Anaesth 1994;72:497.
56. McCoy EP, Mirakhur RK. Comparison of the effect of neostigmine and edrophonium on the duration of action of suxamethonium. Acta Anaesthesiol Scand 1995;39:744-7.
57. Shanks CA, Somogyi AA, Triggs EJ. Dose-response and plasma concentration-response relationship of pancuronium in man. Anesthesiology 1979;51:111-18.
58. Agoston S, Feldman SA, Miller RD. Plasma concentrations of pancuronium and neuromuscular blockade after injection into isolated arm, bolus injection, and continuous infusion. Anesthesiology 1979;51:119-22.
59. Wintersteiner O, Dutcher JD. Curare alkaloids from Chondodendron tomentosum. Science 1943;97:467-70.
60. Matteo RS, Nishitateno K, Pua EK, Spector S. Pharmacokinetics of d-tubocurarine in man: effect of an osmotic diuretic on urinary excretion. Anesthesiology 1980;52:335-8.
61. Amaki Y, Waud BE, Waud DR. Atracurium-receptor kinetics: simple behavior from a mixture. Anesth Analg 1985;64:777-80.
62. Stenlake JB, Waigh RD, Dewar GH, Dhar NC, Hughes R, Chapple DJ, et al. Biodegradable neuromuscular blocking agents. Part 6: Stereochemical studies on atracurium and related polyalkylene diesters. Eur J Med Chem 1984;19: 441-50.
63. Tsui D, Graham GG, Torda TA. The pharmacokinetics of atracurium isomers in vitro and in humans. Anesthesiology 1987;67:722-8.
64. Robertson EN, Booij LHDJ, Fragen RJ, Crul JF. A clinical comparison of atracurium and vecuronium (Org NC45). Br J Anaesth 1983;55:125-30.
65. Griffiths RB, Hunter JM, Jones RM. Atracurium infusions in patients with renal failure on an ITU. Anaesthesia 1986;41:375-81.
66. Hosking MP, Lennon RL, Gronert GA. Combined H1 and H2 receptor blockade attenuates the cardiovascular effects of high dose atracurium for rapid sequence endotracheal intubation. Anesth Analg 1988;67:1089-92.
67. Hughes R, Chapple DJ. The pharmacology of atracurium: a new competitive neuromuscular blocking agent. Br J Anaesth 1981;53:31-44.
68. Stenlake JB, Waigh RD, Dewar GH. Biodegradable neuromuscular blocking agents part 4: atracurium besylate and related polyalkylene di-esters. Europ J Med Chem 1981;16: 515-24.
69. Kent AP, Parker CJR, Hunter JM. Pharmacokinetics of atracurium and laudanosine in the elderly. Br J Anaesth 1989; 63:661-6.
70. Nigrovic V, Banoub M. Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine. Clin Pharmacokinet 1992;22:396-408.
71. Diefenbach C, Abel M, Buzello W. Greater neuromuscular blocking potency of atracurium during hypothermic than during normothermic cardiopulmonary bypass. Anesth Analg 1992;75:675-8.
72. Meretoja OA, Taivaninen T, Wirtavuori K. Pharmacodynamic effects of 51W89, an isomer of atracurium, in children under halothane anaesthesia. Br J Anaesth 1995;74:6-11.
73. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995;82:1139-45.
74. Littlejohn IH, Abhay K, El Sayed A, Broohead CJ, Duvaldestin P, Flynn PJ. Intubating conditions following 1R CIS 1'R CIS atracurium (51W89). Anaesthesia 1995;50:499-502.
75. Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995;82:1131-8.
76. Konstadt SN, Reich DL, Stanley III TE, DePerio M, Chuey C, Schwartzbach C, Abou-Donia M. A two-center comparison of the cardiovascular effects of cisatracurium (Nimbex TM) and vecuronium in patients with coronary artery disease. Anesth Analg 1995;81:1010-14.
77. Eastwood NB, Boyd AH, Parker CJR, Hunter JM: Pharmacokinetics of 1R-cis-1'cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth 1995;75:431-5.
78. Boyd AH, Eastwood NB, Parker CJR, Hunter JM: Pharmacodynamics of the 1R cis-1'R cis isomer of atracurium (51W89) in health and chronic renal failure. Br J Anaesth 1995;74:400-4.
79. Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wasila WB, El-Sayad HA. The clinical neuromuscular pharmacology of Mivacurium chloride (BW B1090U). Anesthesiology 1988;68:723-32.
80. Maehr RB, Belmont MR, Wray DL, Savarese JJ, Wastila WB. Autonomic and neuromuscular effects of mivacurium and isomer in cats. Anesthesiology 1991;75:A772.
81. Head-Rapson AG, Devlin JC, Parker CJR, Hunter JM. Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. Br J Anaesth 1995;75:31-6.
82. Stoops CM, Curtis CA, Kovach DA, McCammon RL, Stoelting RK, Warren TM, Miller D, Bopp SK, Jugovic DJ, Abou-Donia MM. Hemodynamic effects of Mivacurium chloride administered to patients during oxygen-sufentanil anesthesia for coronary artery bypass grafting or valve replacement. Anesth Analg 1989;68:333-9.
83. Stoops CM, Curtis CA, Kovach DA, McCammon RL, Stoelting RK, Warren TM, Miller D, Bopp SK, Jugovic DJ, Abou-Donia MM. Hemodynamic effects of Mivacurium chloride administered to patients during oxygen-sufentanil anesthesia for coronary artery bypass grafting or valve replacement. Anesth Analg 1989;68:333-9.
84. Savarese JJ, Ali HH, Basta SJ, Scott RPF, Embree PB, Wastila WB, Abou-Donia MM, Gelb C. The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. Anesthesiology 1989;70:386-94.
85. Goldhill DR, Whitehead JP, Emmott RS, Griffith AP, Bracey BJ, Flynn PJ. Neuromuscular and clinical effects of mivacurium chloride in healthy adult patients during nitrous oxide-enflurane anaesthesia. Br J Anaesth 1991;67:289-95.
86. Naguib M, Abdulatif M, Selim M, Al-Ghamdi A. Dose-response studies of the interaction between mivacurium and suxamethonium. Br J Anaesth 1995;74:26-30.
87. Goudsouzian NG, Alifirmoff JK, Eberly C, Smeets R, Griswold J, Miller V, McNulty BF, Savarese JJ. Neuromuscular and cardiovascular effects of mivacurium in children. Anesthesiology 1989;70:237-42.
88. Cook DR, Stiller RL, Weakly JN, Chakravorti S, Brandom BW, Wlech RM. In vitro metabolism of Mivacurium chloride (BW B1090U) and succinylcholine. Anesth Analg 1989;68:452-6.
89. Ostergaard D, Jensen FS, Jensen E, Viby-Mogensen J. Influence of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular blockade. Acta Anaesthesiol Scand 1989;33 suppl. 191:164.
90. Ostergaard D, Janden E, Jensen FS, Viby-Mogensen J. The duration of action of mivacurium induced neuromuscular block in patients homozygous for the atypical plasma cholinesterase gene. Anesthesiology 1991;75:A774.
91. Ostergaard D, Jensen FS, Jensen E, Skovgaard LT, Viby-Mogensen J. Influence of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular blockade in phenotypically normal patients. Acta Anaesthesiol Scand 1992;36:702-6.
92. Goudsouzian NG, d'Hollander AA, Viby-Mogensen J. Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency. Anesth Analg 1993;77:183-5.
93. Maddineni VR, Mirakhur RK. Prolonged neuromuscular block following mivacurium. Anesthesiology 1993;71:227-31.
94. Sockalingam I, Green DW. Mivacurium-induced prolonged neuromuscular block. Br J Anaesth 1995;74:234-6.
95. Fox MW, Hunt PCW. Prolonged neuromuscular block associated with mivacurium. Br J Anaesth 1995;74:237-8.
96. Diefenbach C, Abel M, Rump AFE, Grond S, Korb H, Buzello W. Changes in plasma cholinesterase activity and mivacurium neuromuscular block in response to normothermic cardiopulmonary bypass. Anesth Analg 1995;80:1088-91.
97. Petersen RS, Bailey PL, Kalameghan R, Ashwood ER. Prolonged neuromuscular block after mivacurium. Anesth Analg 1993;76:194-6.
98. Hart PS, Wright PC, Brown R, Lau M, Sharma ML, Miller RD, Gruenke L, Fisher DM. Edrophonium increases mivacurium concentrations during constant mivacurium infusion, and large doses minimally antagonize paralysis. Anesthesiology 1995;82:912-18.
99. Abdulatif M. Recovery characteristics after early administration of anticholinesterases during intensive mivacurium-induced neuromuscular block. Br J Anaesth 1995;74:20-5.
100. Mangar D, Kirchhoff GT, Rose PL, Castellano FC. Prolonged neuromuscular block after mivacurium in a patient with end-stage renal disease. Anesth Analg 1993;76:866-7.
101. Naguib M, El-Grammal M, Daoud W, Ammar A, Moukhtar H, Turkistani A. Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade. Anesthesiology 1995;82:1288-92.
102. Petersen RS, Bailey PL, Kalameghan R, Ashwood ER. Prolonged neuromuscular block after mivacurium. Anesth Analg 1993;76:194-6.
103. Robertson WS, Shaikh J, Purdie DW. Mivacurium sensitivity in a patient heterozygous for the atypical and silent genes for plasma cholinesterase. Ann Clin Biochem 1995;32:431-3.
104. Goudsouzian NG, Alifinoff JK, Eberly C, Smeets R, Grisvold J, Miller V, McNully BF, Savarese JJ. Neuromuscular and cardiovascular effects of mivacurium in children. Anesthesiology 1989;70:237-42.
105. Shanks CA, Fragen RJ, Pemberton D, Katz JA, Rizner ME. Mivacurium induced neuromuscular blockade following single bolus doses and with continuous infusion during either balanced or enflurane anesthesia. Anesthesiology 1989;71: 362-6.
106. Caldwell JE, Kitts JB, Heier T, Fahey MR, Lynam DP, Miller RD. The dose-response relationship of mivacurium chloride in humans during nitrous oxide-fentanyl or nitrous oxideenflurane anesthesia. Anesthesiology 1989;70:31-5.
107. Maddineni VR, Cooper R, Stanley JC, Mirakhur RK, Clarke RSJ. Clinical evaluation of doxacurium chloride. Anaesthesia 1992;47:554-7.
108. Murray DJ, Mehta MP, Choi WW, Forbes RB, Sokoll MD, Gergis SD, Rudd GD, Abou-Donia MM. The neuromuscular blocking and cardiovascular effects of Doxacurium chloride in patients receiving nitrous oxide narcotic anesthesia. Anesthesiology 69;1988:472-7.
109. Basta SJ, Savarese JJ, Ali HH, Embree PB, Schwartz AF, Rudd GD, Wastila WB. Clinical pharmacology of Doxacurium chloride. Anesthesiology 69;1988:478-86.
110. Lennon RL, Hosking MP, Houck PC, Rose SH, Wedel DJ, Gibson BE, Ascher JA, Rudd GD. Doxacurium chloride for neuromuscular blockade before tracheal intubation and surgery during nitrous oxide-oxygen-narcotic-enflurane anesthesia. Anesth Analg 1989;68:225-60.
111. Schmith VD, Fiedler-Kelly J, Abou-Donia M, Huffman CS, Grasela TH, Jr. Population pharmacodynamics of doxacurium. Clin Pharmacol Ther 1992;52:528-36.
112. Stoops CM, Curtis CA, Kovach DA, McCammon RL, Stoelting RK, Warren TM, Miller D, Abou-Donia MM. Hemodynamic effects of Doxacurium chloride in patients receiving oxygen sufentanil anesthesia for coronary artery bypass grafting or valve replacement. Anesthesiology 1988;69:365-70.
113. Emmott RS, Bracey DJ, Goldhill DR, Yate PM, Flynn PJ. Cardiovascular effects of doxacurium, pancuronium, and vecuronium in anaesthetised patients presenting for coronary artery bypass surgery. Br J Anaesth 1990;65:480-6.
114. Cashman JN, Luke J, Jones RM. Neuromuscular block with doxacurium (BE A938U) in patients with normal or absent renal function. Br J Anaesth 1990;64:186-92.
115. Cook DR, Freeman JA, Lai AA, Robertson KA, Kang Y, Stiller RL, Aggarwal S, Abou-Donia MM, Welch RM. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and those with hepatic or renal failure. Anesth Analg 1991;72:145-50.
116. Reich DL. Transient systemic hypotension and cutaneous flushing in response to doxacurium chloride. Anesthesiology 1989;71:783-5.
117. Katz JA, Fragen RJ, Shanks CA, Dunn K, McNulty B, Rudd GD. Dose-response relationships of doxacurium chloride in humans during anesthesia with nitrous oxide and fentanyl, enflurane, isoflurane, or halothane. Anesthesiology 1989;70: 432-6.
118. Goudsouzian NG, Alifimoff JK, Liu LMP, Foster VJ, McNulty BF, Savarese JJ. Neuromuscular and cardiovascular effects of doxacurium in children anaesthetized with halothane. Br J Anaesth 1989;62:263-8.
119. Sarner JB, Brandom BW, Cook DR, Dong ML, Horn MC, Woelfel SK, Davis PJ, Rudd GD, Foster VJ, McNulty BF. Clinical pharmacology of doxacurium chloride (BW 938U) in children. Anesth Analg 1988;67:303-6.
120. Scott RPF, Norman J. Doxacurium chloride: A preliminary clinical trial. Br J Anaesth 1989;62:373-7.
121. Hughes R. Evaluation of the neuromuscular blocking properties and side-effects of the two new isoquinolinium bisquarternary compounds (BW 252C64 and BW 403C65). Br J Anaesth 1972;44:27-42.
122. Fiamengo SA, Savarese JJ, Chiscolm D, Lien C, Wastila WB. Pharmacology of BW954U. Anesthesiology 1990;73:A863.
123. Huu-Lainé FK, Pingo-Scognamiglio W. Activité curarisante du dichlorure de 3β-20α bistrimethylammonium 5α-prégnane (malouétine) et de ses stéréoisomères. Arch Int Pharmacodyn Thér 1964;147:209-19.
124. Bucket WR, Hewet CL, Savage DS. Pancuronium bromide and other steroidal neuromuscular blocking agents containing acetylcholine fragments. J Med Chem 1973;16:1116-24.
125. Durant NN, Marshall IG, Savage DS, Nelson DJ, Sleigh T, Carlyle IC. The neuromuscular and autonomic blocking activities of pancuronium, Org. NC45, and other pancuronium analogues, in the cat. J Pharm Pharmacol 1979;31:83-7.
126. Marshall IG, Agoston S, Booij LHDJ, Durant NN, Foldes FF. Comparison of the cardiovascular actions of Org.NC45 with those produced by other non-depolarizing neuromuscular blocking agents in experimental animals. Br J Anaesth 1980;52:21S-32S.
127. Naguib M, Samarkandi AH, Bakhamees HS, Magboul MA, El-Bakry AK. Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids. Br J Anaesth 1995;75:37-42.
128. Krieg N, Crul JF, Booij LHDJ. Relative potency of Org NC45, pancuronium, alcuronium and tubocurarine in anaesthetized man. Br J Anaesth 1980;52:783-8.
129. Miller RD, Agoston S, Booij LHDJ, Kersten UW, Crul JF, Ham J. The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. J Pharmacol Exp Ther 1978;207;539-43.
130. Bergin AM, Clarke TA, Matthews TG. Problems with pancuronium in the neonatal intensive care unit. Irish Med J 1988;81:39-40.
131. Fahey MR, Morris RB, Miller RD, Nguyen TL, Upton RA. Pharmacokinetics of Org NC45 (Norcuron) in patients with and without renal failure. Br J Anaesth 1981;53:1049-53.
132. Bencinin AF, Scaf AHJ, Sohn YJ, Meistelman C, Lienhart A, Kersten UW, Schwarz S, Agoston S. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesth Analg 1986;65:245-51.
133. Wright PMC, Hart P, Lau M, Sharma ML, Gruenke L, Fisher DM. Cumulative characteristics of atracurium and vecuronium. Anesthesiology 1994;81:59-68.
134. Caldwell JE, Szenohradszky J, Segredo V, Wright PMC, McLoughlin C, Sharma ML, Gruenke LD, Fisher DM, Miller RD. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (Org 7268) and its parent compound, vecuronium, in human volunteers. J Pharmacol Exp Ther 1994;270:1216-22.
135. Stanley JC, Mirakhur RJ. Comparative potency of pipecuronium bromide and pancuronium bromide. Br J Anaesth 1989;63:754-5.
136. Fitzal S, Ilias W, Kalina K, Schwarz S, Foldes FF, Steinbereithner K, Neuromuskulare und kardiovaskulare Effekte von Duador, einem neuen kurz wirksamen nicht depolarisierenden Muskelrelaxans. Anaesthesist 1982;32: 674-9.
137. Dubois MY, Fleming NW, Lea DE. Effects of succinylcholine on the pharmacodynamics of pipecuronium and pancuronium. Anesth Analg 1991;72:364-8.
138. Caldwell JE, Castagnoli KP, Canfell PC, Fahey MR, Lynam DP, Fisher DM, Miller RD. Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. Br J Anaesth 1988;61:693-7.
139. Pittet JF, Tassonyi E, Morel DR, Gemperle G, Richter M, Rouge JC. Pipecuronium-induced neuromuscular blockade during nitrous oxide-fentanyl, isoflurane, and halothane anesthesia in adults and children. Anesthesiology 1989;71:210-13.
140. Abdulatif M, Naguib M. Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade. Can J Anaesth 1991;38:159-63.
141. Stanley JC, Carson IW, Gibson FM, McMurray TJ, Elliott P, Lyons SM, Mirakhur RK. Comparison of the haemodynamic effects of pipecuronium and pancuronium during fentanyl anaesthesia. Acta Anaesthesiol Scand 1991;35:262-6.
142. Tassonyi E, Neidhart P, Pittet JF, Morel DR, Gemperle M. Cardiovascular effects of pipecuronium and pancuronium in patients undergoing coronary artery bypass grafting. Anesthesiology 1988;69:793-6.
143. Barankay A. Circulatory effects of pipecuronium bromide during anaesthesia of patients with severe valvular and ischaemic heart disease. Drug Res 1980;30:386-9.
144. Wierda JMKH, Karliczek GF, Vandenbrom RHG, Pinto I, Kersten, Kleef UW, Meyer DK, et al. Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. Can J Anaesth 1990;37:183-91.
145. Wierda JMKH, Szenohradszky J, de Wit APM, Zentai G, Agoston S, Kakas M, Kleef UW, Meyer DK. The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide (Arduan). Eur J Anaesthesiol 1991;8:451-7.
146. Lapreye G, Dubois M, Lea D, Kataria B, Tram D. Effects of 3 intubating doses of Org 9426 in humans. Anesthesiology 1990;73:A906.
147. Foldes FF, Nagashima H, Nguyen HD, Schiller WS, Mason MM, Ohta Y. The neuromuscular effects of Org 9426 in patients receiving balanced anesthesia. Anesthesiology 1991;75:191-5.
148. Cooper R, Mirakhur RK, Clarke RSJ, Boules ZS. Comparison of intubating conditions after administration of Org 9426 (rocuronium) and suxamethonium. Br J Anaesth 1992;69:269-73.
149. Huizenga ACT, Vandenbrom RHG, Wierda JMKH, Hommes FDM, Hennis PJ. Intubating conditions and onset of neuromuscular block of rocuronium (ORG 9426);a comparison with suxamethonium. Acta Anaesthesiol Scand 1992;36:463-8.
150. Pühringer FK, Khuenl-Brady K, Koller J, Mitterschiffthaler G. Evaluation of the endotracheal intubating conditions of rocuronium (ORG 9426) and succinylcholine in outpatient surgery. Anesth Analg 1992;75:37-40.
151. Wierda JMKH, de Wit APM, Kuizinga K, Agoston S. Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent. Br J Anaesth 1990;64:521-3.
152. Davis GK, Sziam F, Lowdon JD, Levy JH. Evaluation of histamine release following Org 9426 administration using a new radioimmunoassay. Anesthesiology 1991;75:A818.
153. McCoy EP, Maddineni VR, Elliot P, Mirakhur RK, Caroon IW, Cooper RA. Haemodynamic effects of rocuronium during fentanyl anaesthesia: comparison with vecuronium. Can J Anaesth 1993;408:703-8.
154. Quil TJ, Begin M, Glass PSA, Ginsberg B, Gorback MS. Clinical responses to Org 9426 during isoflurane anesthesia. Anesth Analg 1991;72:203-6.
155. Dubois M, Kataria B, Lea D, Lapeyre G. Neuromuscular effects of Org 9426 in humans during general anesthesia with and without enflurane. Anesth Analg 1991;72:S57.
156. Cooper RA, Mirakhur RK, Maddineni VR. Neuromuscular effects of rocuronium bromide (Org 9426) during fentanyl and halothane anaesthesia. Anaesthesia 1993;48:103-5.
157. Naguib M, Abdulatif M, Al-Ghamdi A. Dose-response relationships for edrophonium and neostigmine antagonism of rocuronium bromide (ORG 9426)-included neuromuscular blockade. Anesthesiology 1993;79:739-45.
158. Wierda JMKH, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 1991;38:430-5.
159. Khuenl-Brady K. Castagnoli KP, Canfell C, Caldwell JE, Agoston S, Miller RD. The neuromuscular blocking effect and pharmacokinetics of Org 9426 and Org 9616 in the cat. Anesthesiology 1990;72:669-74.
160. Szenohradszky J, Fisher DM, Segredo V, Caldwell JE, Bragg P, Sharma ML. Pharmacokinetics of rocuronium bromide (Or g 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology 1992;77:899-904.
161. Cooper R, Mirakhur RK, Clarke RSJ, Boules ZS. Comparison of intubating conditions after administration of Org 9426 (rocuronium) and suxamethonium. Br J Anaesth 1992;69: 269-73.
162. Pühringer FK, Khuenl-Brady K, Koller J, Mitterschiffthaler G. Evaluation of the endotracheal intubating conditions of rocuronium (Org 9426) and succinylcholine in outpatient surgery. Anesth Analg 1992;75:37-40.
163. Cason B, Baker DG, Hickey RF, Miller RD, Agoston S. Cardiovascular and neuromuscular effects of three steroidal neuromuscular blocking drugs in dogs (Org 9616, Org 9426, Org 9991). Anesth Analg 1990;70:382-8.
164. Baird WLM. Initial studies in man with a new myoneural blocking agent (Org 6368). Br J Anaesth 1974;46:658-61.
165. Booij LHDJ, Crul JF, van der Pol F. Cardiovascular and neuromuscular blocking effects of four new muscle relaxants in anaesthetized Beagle dogs. Eur J Anaesthesiol 1988;6:70.
166. Muir AW, Houston J, Marshall RJ, Bowman WC, Marshall IG. A comparison of the neuromuscular blocking and autonomic effects of two new short-acting muscle relaxants with those of succinylcholine in the anesthetized cat and pig. Anesthesiology 1989;70:533-40.
167. Gilly H, Hirtschl MM, Steinbereithner K. Pharmacodynamics of Org 8764, atracurium and vecuronium: a comparison of vocal cord, diaphragm and tibial muscle relaxation. Anesthesiology 1988;69:A481.
168. Muir AW, Anderson K, Marshall RJ, Booij LHDJ, Crul JF, Prior C, Bowman WC, Marshall IG. The effects of a 16-N-homopiperidino analogue of vecuronium on neuromuscular transmission in anaesthetized cats, pigs, dogs and monkeys, and in isolated preparations. Acta Anaesthesiol Scand 1991;35:85-90.
169. van den Broek L, Wierda JMKH, Prosst JH, Hommes FDM, Agoston S. Clinical pharmacology of Org 7617, a short acting non-depolarizing neuromuscular blocking agent. Eur J Clin Pharmacol 1994;46:225-9.
170. Wierda JMKH, Beaufort AM, Kleef UW, Smeulers NJ, Agoston S. Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. Can J Anaesth 1994;41:213-20.
171. van den Broek L, Lambalk LM, Richardson FJ, Wierda JMKH. Dose-response relation, neuromuscular blocking action, intubation conditions, and cardiovascular effects of Org 9273, a new neuromuscular blocking agent. Anesth Analg 1991;72:811-16.
172. Wierda JMKH, Proost JH: Structure-pharmacodynamic-pharmacokinetic relationships of steroidal neuromuscular blocking agents. Eur J Anaesth 1995;12(suppl.11):45-54.
173. Bowman WC, Rodger IW, Houston J, Marshall IG, Mclndewar I. Structure-action relationships among some deacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 1988;89:57-62.
174. Wierda JMKH, van den Broek L, Proost JH, Verbaan BW, Hennis PJ. Time course of action and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant. Anesth Analg 1993;77:579-84.
175. van den Broek L, Wierda JMKH, Smeulers NJ, Proost JH. Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. Br J Anaesth 1994;73:331-5.
176. Gandiha A, Marshall IG, Paul D, Rodger IW, Scott W, Singh H. Some actions of chandonium iodide, a new short-acting muscle relaxant, in anesthetized cats and on isolated muscle preparations. Clin Exp Pharmacol Physiol 1975;2:150-70.
177. Suri YV. Chandonium iodide - New non-depolarizing muscle relaxant. In: Suri YV, Singh D eds. Anesthesiology - clinical pharmacology. Vani Educational Books New Delhi, 1984, pp.28-35. ISBN 0-7069-2559-9.
178. Marshall IG, Paul D, Singh H. The neuromuscular and other blocking actions of 4,17a-Diomethyl-4,17a-Diaza-d-homo-5α androstane dimethiodide (HS-342) in the anaesthetized cat. Eur J Pharm 1973;22:129-34.
179. Fitzal S, Ilias W, Kalina K, Schwarz S, Foldes FF, Steinbereithner K. Neuromuskuläre Effekte von Duador @, einem neuen kurz wirksamen nicht
180. Walker J, Shanks CA, Triggs EJ. Clinical pharmacokinetics of alcuronium chloride in man. Eur J Clin Pharmacol 1990;17:449-57.
181. Ramzan MI, Triggs EJ, Shanks CA. Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. Eur J Clin Pharamacol 1980;17:135-43.
182. Ramzan MI, Shanks CA, Triggs EJ. Gallamine disposition in surgical patients with chronic renal failure. Br J Clin Pharmacol 1981;12:141-7.
183. Savarese JJ, Ginsberg S, Lee CM, Kitz RJ. The pharmacology of new short-acting nondepolarizing ester neuromuscular blocking agents: clinical implications. Anesth Analg 1973; 52:982-8.
184. Savarese JJ, Antonio RP, Ginsberg S. Potential clinical uses of short-acting nondepolarizing neuromuscular-blocking agents as predicted from animal experiments. Anesth Analg 1974;54:669-78.
185. Savarese JJ, Wastila WB. Pharmacology of BW985U: A short acting nondepolarizing neuromuscular blocking agent. Anesthesiology 1979;51:S277.
186. Savarese JJ, Wastila WB. BW444U: an intermediate-duration nondepolarizing blocking agent with significant lack of cardiovascular and autonomic effect. Anesthesiology 1979;51:S279.
187. Wastila WB, Savarese JJ. Autonomic/neuromuscular dose-ratios and hemodynamic effects of BW785U), a short-acting nondepolarizing ester neuromuscular blocking agent. Anesthesiology 51;1979:5278.
188. Savarese JJ, Ali HH, Basta SJ, Ramsey FM, Rosow CE, Lebowitz PW, Lineberry CG, Cloutier G. Clinical neuromuscular pharmacology of BW785U, an ultra-short-acting nondepolarizing ester neuromuscular blocking agent. Anesthesiology 1980;53:S274.
189. Savarese JJ, Basta SJ, Ali HH, Sunder N, Gionfriddo M, Goudsouzian NG, Lineberry CG. Clinical neuromuscular pharmacology of BW444U. Anesthesiology 1981;55:A197.
190. Rosow CE, Basta SJ, Savarese JJ, Ali HH, Kniffen KJ, Moss J. BW785U: correlation of cardiovascular effects with increases in plasma histamine. Anesthesiology 1980;53:S271.
191. Basta SJ, Moss J, Savarese JJ, Ali HH, Sunder N, Gionfriddo M, Lineberry CG. Cardiovascular effects of BW444U: correlation with plasma histamine levels. Anesthesiology 1981;55:A198.
192. Stenlake JB, Dhar NC, Maehr RB, Scharver J, Wastila WB, Midgley JH. Neuromuscular blocking agents. Approaches to short-acting compounds 2. Bis-thiazolium salts. Eur J Med Chem 1993;28:415-18.
193. Foldes FF, Chaudhry IA, Barakat T, Flores CA, Kinjo M, Bikkhazi GB, Nagashima H. Species variation in the site and mechanism of the neuromuscular effects of diadonium in rodents. Anesth Analg 1989;68:638-44.
194. Mitenko PA, Ogilvie RI (1972) Rapidly achieved plasma concentration plateaus, with observations on theophylline kinetics. Clin Pharmacol Ther 13:329-35.
195. Somogyi AA, Shanks CA, Triggs EJ (1977a) Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anaesth 49:1103-8.
196. Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979;301:409-13.
197. Garrett ER. Pharmacokinetics and clearances related to renal processes. Int J Clin PharmacolBiopharm. 1978;16:155-72.
198. Agoston S, Vermeer GA, Kersten UW, A preliminary investigation of the renal and hepatic elimination of gallamine triethiodide in man. Br J Anaesth 1978;50:345-51.
199. Miller RD, Matteo RD, Benet LZ, Sohn YJ. The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther 1977;12:23-9.
200. Philips BJ, Hunter JM. Use of mivacurium chloride by constant infusion in the anephric patient. Br J Anaesth 1992;68:492-8.
201. Mangar D, Kirchhoff GT, Rose PL, Castellano FC. Prolonged neuromuscular block after mivacurium in a patient with end-stage renal disease. Anesth Analg 1993;76:866-7.
202. Cooper RA, maddineni VR, Mirakhur RK, Wierda JMKH, Brady M, Fitzpatrick KTJ. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993;71:222-6.
203. Caldwell JE, Canfell PC, Castagnolie KP, Lynam DP, Fahey MR, Fisher DM, Miller RD. The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anaesthetized with halothane and nitrous oxide. Anesthesiology 1989;70:7-12.
204. Westra P, Keulemans GTP, Houwertjes MC, Hardonk MJ, Meijer DKF. Mechanisms underlying the prolonged duration of action of muscle relaxants caused by extrahepatic cholestasis. Br J Anaesth 1981;53:217-27.
205. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90.
206. Khalil M, D'Honneur G, Duvaldestin P, Slavov V, De Hys C, Gomeni R. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 1994;80:1241-7.
207. Magorian T, Wood P, Caldwell J, Fisher D, Segredo V, Szenohradszky J, Sharma M, Gruenke L, Miller R. The pharmacokinetics and neuromuscular effects of rocuronium bromide patients with liver disease. Anesth Analg 1995;80:754-9.
208. Ono K, Nagano O, Ohta Y, Kosaka F. Neuromuscular effects of respiratory and metabolic acid-base changes in vitro with and without non-depolarizing muscle relaxants. Anesthesiology 1990;73:710-16.
209. 2-induced acid-base changes on the potencies of muscle relaxants and antagonism of neuromuscular block by neostigmine in rat in vitro. Anesth Analg 1994;78:322-7.
210. Buzello W, Pollmaecher T, Schluermann D, Urbanyi B. The Influence of hypothermic cardiopulmonary bypass on neuromuscular transmission in the absence of muscle relaxants. Anesthesiology 1986;64:279-81.
211. Buzello W, Schluermann D, Schindler M, Spillner G. Hypothermic cardiopulmonary bypass and neuromuscular blockade by pancuronium and vecuronium. Anesthesiology 1985;62:201-4.
212. Miller RD, Agoston S, van der Pol F, Booij LHDJ, Crul JF, Ham J. Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. J Pharmacol Exp Ther 1978;207:532-8.
213. Buzello W, Schluermann D, Pollmaecher T, Spillner G. Unequal effects of cardiopulmonary bypass-induced hypothermia on neuromuscular blockade from constant infusion of alcuronium, d-tubocurarine, pancuronium, and vecuronium. Anesthesiology 1987;66:842-6.
214. Denny NM, Kneeshaw JD. Vecuronium and atracurium infusions during hypothermic cardiopulmonary bypass. Anesthesia 1986;41:919-22.
215. Heier T, Caldwell JE, Sessler DI, Kitts JB, Miller RD. The relationship between adductor pollicis twitch tension and core, skin, and muscle temperature during nitrous oxide isoflurane anesthesia in humans. Anesthesiology 1989;71:381-4.
216. Heier T, Caldwell JE, Sessler DI, Miller RD. The effect of local surface and central cooling on adductor pollicis twitch tension during nitrous oxide/isoflurane and nitrous oxide/fentanyl anesthesia in humans. Anesthesiology 1990;72:807-11.
217. Heier T, Caldwell JE, Sessler DI, Miller RD. Mild hypothermia increases duration of action and spontaneous recovery of vecuronium blockade during nitrous oxide-isoflurane anesthesia in humans. Anesthesiology 1991;74:815-19.
218. Heier T, Caldwell JE, Eriksson LI, Sessler DI, Miller RD. The effect of hypothermia on adductor pollicis twitch tension during continuous infusion of vecuronium in isofluraneanesthetized humans. Anest Analg 1994;78:312-17.
219. Smith RB, Grenvik A. Cardiac arrest following succinylcholine in patients with central nervous system injuries. Anesthesiology 1970;33:558-60.
220. Cooperman LH, Strobel GE Jr., Kennell EM. Massive hyperkalemia after administration of succinylcholine. Anesthesiology 1979;32:161-4.
221. Cowgill DB, Mostello LA, Shapiro HM. Encephalitis and a hyperkalemic response to succinylcholine. Anesthesiology 1974;40:409-11.
222. Stevenson PH, Birch AA. Succinylcholine-induced hyperkalemia in a patient with a closed head injury Anesthesiology 1979;51:89-90.
223. Iwatsuki N, Kuroda N, Amaha K, Iwatsuki K. Succinylcholine induced hyperkalemia in patients with ruptured cerebral aneurysm. Anesthesiology 1980;53:64-7.
224. Feldman JM. Cardiac arrest after succinylcholine administration in a pregnant patient recovering from Guillain-Barré syndrome. Anesthesiology 1990;72:942-4.
225. Gronert GA, Lambert EH, Theye RA. The response of denervated skeletal muscle to succinylcholine. Anesthesiology 1973;39:13-22.
226. Moorthy SS, Hilgenberg JC. Resistance to non-depolarizing muscle relaxants in paretic upper extremities of patients with residual hemiplegia. Anesth Analg 1980;59:624-7.
227. Shayevitz JR, Matteo RS. Decreased sensitivity tometocurine in patients with upper motorneuron disease. Anest Analg 1985;64:767-72.
228. Gronert GA, Theye RA. Effect of succinylcholine on skeletal muscle with immobilization atrophy. Anesthesiology 1974;40:268-71.
229. Fiacchino F, Gemma M, Bricchi M, Giombini S, Regi B. Sensitivity to curare in patients with upper and lower motor neurone dysfunction. Anaesthesia 1991;46:980-2.
230. Rosenbaum KJ, Neigh JL, Strobel GE. Sensitivity to nondepolarizing muscle relaxants in amyotrophic lateral sclerosis: report of two cases. Anesthesiology 1971;35:638-41.
231. Stone WA, Beach TP, Hamelberg W. Succinylcholine-danger in the spinal-cord-injured patient. Anesthesiology 1970;32:168-9.
232. Tobgey RE. Paraplegia, succinylcholine and cardiac arrest. Anesthesiology 1970;32:359-64.
233. Hogue Jr CW, Itani MS, Martyn JAJ. Resistance to d-tubocurarine in lower motor neuron injury is related to increased acetylcholine receptors at the neuromuscular junction. Anesthesiology 1990;73:703-9.
234. Greenawalt III, JW. Succinylcholine-induced hyperkalemia 8 weeks after a brief paraplegic episode. Anesth Analg 1992;75:294-5.
235. Orndahl G, Sternberg K. Myotonic human musculature: stimulation with depolarizing agents. Mechanical registration of the effect of succinylcholine, succinylmonocholine, and decamethonium. Acta Med Scand 1962;172:3 (suppl.389):3-29.
236. Azar I. The response of patients with neuromuscular disorders to muscle relaxants: a review. Anesthesiology 1984; 61:173-87.
237. Weintraub MI, Megahed MS, Smith BH. Myotonic-like syndrome in multiple sclerosis. NY State J Med 1970;70:677-9.
238. Takamori M, Takahashi M, Yasukawa Y, Iwasa K, Nemoto Y, Suenga A, Nagataki S, Nakamura T. Antibodies to recombinant synapototagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci 1995; 133:95-101.
239. Tempelhoff R, Modica PA, Jellish WS, Spitznagel EL. Resistance to atracurium-induced neuromuscular blockade in patients with intractable seizure disorders treated with anticonvulsants. Anesth Analg 1990;71:665-7.
240. Lambert JJ, Durant NN, Henderson EG. Drug-induced modifications of ionic conductance at the neuromuscular junction. Ann Rev Pharmacol Toxicol 1983;23:505-39.
241. Gage PW, Hamill OP. Effects of anesthetics on ion channels in synapses. Int Rev Physiol 1981;25:1-45.
242. Bufler J, Pichlmeier R, Schneck HJ, Hussman H, Franke C. Block of nicotinic acetylcholine-activated channels of cultured mouse myotubes by isoflurane. Neuroscie Letters 1994;168;135-8.
243. Dilger JP, Brett RS, Mody HI. Effects of isoflurane on acetylcholine receptor channels. 2. Currents elicited by rapid perfusion of acetylcholine. Mol Pharmacol 1993;44:1056-63.
244. Liu YI, Dilger JP, Vidai AM. Effects of alcohols and volatile anesthetics on the activation of nicotinic acetylcholine receptor channels. Mol Pharmacol 1994;45:1235-41.
245. Taivainen T, Meretoja OA. The neuromuscular blocking effects of vecuronium during sevoflurane, halothane and balanced anaesthesia in children. Anaesthesia 1995;50: 1046-9.
246. Caldwell JE, Magorian T, Lynam DP, Segredo V, Eger II EI, Miller RD. Desflurane versus isoflurane: dose-response relationships of pancuronium and succinylcholine. Anesthesiology 1990;73:A860.
247. Witkowski TA, Azad SS, Bartkowski RR, Epstein RH, Marr A, Lessin J. Desflurane (1-653) potentiation of pancuronium bromide: a comparison with isoflurane. Anesthesiology 1990;73:A903.
248. Smiley RM, Ornstein E, Mathews D, Matteo RS. A comparison of the effects of desflurane and isoflurane on the action of atracurium in man. Anesthesiology 1990;A882.
249. Swen J, Gencarelli PJ, Koot HWJ. Vecuronium infusion dose requirements during fentanyl and halothane anesthesia in humans. Anesth Analg 1985;64:411-14.
250. Torda TA, Gage PW. Postsynaptic effect of I.V. anaesthetic agents at the neuromuscular junction. Br J Anaesth 1977;49: 771-6.
251. Wachtel RE, Wegrynowicz ES. Kinetics of nicotinic acetylcholine ion channels in the presence of intravenous anaesthetics and induction agents. Br J Pharmacol 1992;106:623-7.
252. Charlesworth P, Richards CD. Anaesthetic modulations of nicotinic ion channel kinetics in bovine chromaffin cells. Br J Pharmacol 1995;114:909-17.
253. Booij LHDJ, Miller RD, Crul JF. Neostigmine and 4-aminopyridine antagonism of lincomycin-pancuronium neuromuscular blockade in man. Anesth Analg 1978;57:316-21.
254. Sokoll MD, Gergis SD. Antibiotics and neuromuscular function. Anesthesiology 1981;55:148-59.
255. Singh YN, Marshall IG, Harvey AL. Pre- and postjunctional blocking effects of aminoglycosides, polymyxin, tetracyclin and lincosamide antibiotics. Br J Anaesth 1982;54:1295-1305.
256. Fiekers JF. Neuromuscular block produced by polymyxin B-interaction with endplate ion channels. Eur J Pharmacol 1981;70:77-81.
257. Singh YN, Marshall IG, Harvey AL. Depression of transmitter release and postjunctional sensitivity during neuromuscular block produced by antibiotics. Br J Anaesth 1979;51:1027-33.
258. Singh YN, Marshall IG, Harvey AL. Some effects of the aminoglycoside antibiotic amikacin on neuromuscular and autonomic transmission. Br J Anaesth 1978;50:109-17.
259. Wright JM, Collier B. The site of the neuromuscular block produced by polymyxin B and rolitetracycline. Can J Physiol Pharmacol 1976;54:926-36.
260. Wright JM, Collier B. Characterization of the neuromuscular block produced by clindamycin and lincomycin. Can J Physiol Pharmacol 1976;56:937-44.
261. Booij LHDJ, Miller RD, Crul JF. Neostigmine and 4-aminopyridine antagonism of lincomycin-pancuronium neuromuscular blockade in man. Anesth Analg 1978;57:316-21.
262. Kornfeld P, Horowitz SH, Genkins G, Papatestas AE. Myasthenia gravis unmasked by antiarrhythmic agents. Mount Sinai J Med 1976;43:10-14.
263. Stoelting RK. Serum cholinesterase activity following pancuronium and antagonism with neostigmine or pyridostigmine. Anesthesiology 1976;45:674-8.
264. Rautoma P, Erkola O, Meretoja OA. Synergism between mivacurium and pancuronium in adults. Acta Anaesthesiol Scand 1995;39:733-7.
265. Waud BE, Waud DR. Quantitative examination of the interaction of competitive neuromuscular blocking agents on the indirectly elicited twitch. Anesthesiology 1984;61:420-7.
266. Naguib M, Samarkandi AH, Bakhamees HS, Magboul MA, El-Bakry AK. Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids. BJA 1995;75:37-42.
267. Camp CE, Tessen J, Adenwala J, Joyce TH, 3rd. Vecuronium and prolonged neuromuscular block in postpartum patients. Anesthesiology 1987;67:1006-8.
268. 2-receptor antagonist premedication on the duration of vecuronium-induced neuromuscular blockade in postpartum patients. Anesthesiology 1989;71:175-7.
269. Kroeker KA, Beattie WS, Yang H. Neuromuscular blockade in the setting of chronic nicotinic exposure. Anesthesiology 1994;81:A1120.
270. Teiriä H, Rautoma P, Yli-Hankala A. Effect of smoking on dose requirements for vecuronium. Br J Anaesth 1996;75:154-5.
271. Lambert JJ, Durant NN, Handerson EG. Drug-induced modification of ionic conductance at the neuromuscular junction. Ann Rev Pharmacol Toxicol 1983;23:505-39.
272. Wali FA. Interactions of nifedipine and diltiazem with muscle relaxants and reversal of neuromuscular blockade with edrophonium and neostigmine. J Pharmacol (Paris) 1986;17: 244-53.
273. Doll DC, Rosenberg H. Antagonism of neuromuscular blockade by theophylline. Anesth Analg 1979;58:139-40.
274. Ramanathan J, Sibai BM, Pillai R, Angel JJ. Neuromuscular transmission studies in preecclamptic women receiving magnesium sulfate. Am J Obstet Gynecol 1988;158:40-6.
275. Crosby E, Robblee JA. Cyclosporine-pancuronium interaction in a patient with a renal allograft. Can J Anaesth 1988;35:300-2.
276. Hickey DR, Sangwan S, Bevan JC. Phenytoin-induced resistance to pancuronium. Anaesthesia 1988;43:757-9.
277. Loflin MJ. Interaction of pancuronium and corticosteroids. Anesthesiology 1977;47:471-2.
278. Reddy P, Guzman A, Robalino J, Shevde K. Resistance to muscle relaxants in a patient receiving prolonged testosterone therapy. Anesthesiology 1989;70:871-3.
279. Parr SM, Robinson BJ, Rees D, Galletly DC. Interaction between betamethasone and vecuronium. Br J Anaesth 1991;67:447-51.
280. Parr SM, Galletly DC, Robinson BJ. Betamethasone induced resistance to vecuronium: a potential problem in neurosurgery? Anesth Intens Care 1991;19:103-5.
281. Vervloet D. Allergy to muscle relaxants and related compounds. Clin Allergy 1985;15:501-8.
282. Shorten GD. Postoperative residual curarisation: incidence, aetiology and associated morbidity. Anaesth Int Care 1993;21:782-9.
283. Clarke RSJ, Mirakhur RK. Adverse effects of muscle relaxants. Adv Drug React Toxicol Rev 1994;13:23-41.
284. Bowman WC. Non-relaxant properties of neuromuscular blocking drugs. Br J Anaesth 1982;54:147-60.
285. Clayton D. Asystole associated with vecuronium. Br J Anaesth 1986;58:937.
286. Starr NH, Sethna DH, Estafanous FG. Bradycardia and asystole following the rapid administration of sufentanil with vecuronium. Anesthesiology 1986;64:521-3.
287. Cozanitis DA, Erkola O. A clinical study into the possible intrinsic bradycardic activity of vecuronium. Anaesthesia 1989;44:648-50.
288. Wierda JMKH, Maestrone E, Bencini AF, Boyer A, Rashkovsky OM, Lip H, Karliczek R, Ket JM, Agoston S. Haemodynamic effects of vecuronium. Br J Anaesth 1989;62:194-8.
289. Bergin AM, Clarke TA, Matthews TG. Problems with pancuronium in the neonatal intensive care unit. Irish Med J 1988;81:39-40.
290. Kinjo M, Nagashima H, Vizi ES. Effect of atracurium and laudanosine on the release of 3H-noradrenaline. Br J Anaesth 1989;62:683-90.
291. Robertson EN, Hull JM, Verbeek AM, Booij LHDJ. A comparison of rocuronium and vecuronium, the pharmacodynamics, cardiovascular and intra-ocular effects. Eur J Anaesthesiol 1994;9:116-21.
292. McCoy EP, Maddenini VR, Elliot P, Mirakhur RK, Caroon IW, Cooper RA. Haemodynamic effects of rocuronium during fentanyl anaesthesia: comparison with vecuronium. Can J Anesth 1993;408:703-8.
293. Pedersen T, Eliasen K, Henriksen E. A prospective study of risk factors and cardiopulmonary complications associated with anaesthesia and surgery: risk indicators of cardiopulmonary morbidity. Acta Anaesthesiol Scand 1990;34:144-55.
294. Zelcer J, Wells DG. Anaesthetic-related recovery room complications. Anaesth Intens Care 1987;15:168-74.
295. Basta SJ. Modulation of histamine release by neuromuscular blocking drugs. Curr Opin Anaesthesiol 1992;5:572-6.
296. Booij LHDJ, Krieg NN, Crul JF. Intradermal histamine releasing effect caused by Org-NC 45. A comparison with pancuronium, metocurine and d-tubocurarine. Acta Anaesthesiol Scand 1980;24:393-4.
297. Levy JH, Adelson D, Walker B. Wheal and flare responses to muscle relaxants in humans. Agents and Actions 1991;34: 302-8.
298. Vervloet D, Arnaud A, Senft M, Dor P, Bongrand P, Charpin C, Alazia M. Leucocyte histamine release to suxamethonium in patients with adverse reactions to muscle relaxants. J Allergy Clin Immunol 1985;75:338-42.
299. 2-sufentanil anesthesia. Anesth Analg 1994;78:318-21.
300. Moss J, Rosow CE. Histamine release by narcotics and muscle relaxants in humans. Anesthesiology 1983;59:330-9.
301. Watkins J. Second report from an anaesthetic reactions advisory service. Anaesthesia 1989;44:157-9.